Patricia et al. [25] showed that MT1 is critical for the growth and survival of DNMT3A;NPM1-mutant AML cells and nominated MT1 as a key marker for the treatment and prevention of DNMT3A;NPM1-mutant AML. This evidence concerns the gene DNMT3A and acute myeloid leukemia.